A Study to Learn About the Effects of Felzartamab on Daily Living Activities and Its Safety in Adults With Generalized Myasthenia Gravis (gMG) Ages 18 to 80 Years Old (MYAMERGE)

November 10, 2026 updated by: Biogen

A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Felzartamab Compared to Placebo in Adults With Generalized Myasthenia Gravis

In this study, researchers will learn more about the effects of felzartamab, also known as BIIB148, in adult participants with generalized myasthenia gravis, also known as gMG. This is a type of autoimmune disease that affects the signals sent between nerve cells and the muscles. An autoimmune disease means the body's immune system attacks its own healthy cells.

In people with gMG, the body's immune system makes abnormal antibodies that affect the signals that can be sent between the muscle and the nerves at the neuromuscular junction. The neuromuscular junction is where the nerve and muscle connect. The most common antibodies made in gMG are those that target 1 of 2 types of proteins - AchR (acetylcholine receptor) and MuSK (muscle-specific tyrosine kinase).

In this study, researchers wanted to learn more about a study drug called felzartamab. Researchers think felzartamab may lower the amount of antibodies against AChR or MuSK and allow signals between muscles and nerves to be sent normally again.

The main goal of the study is to compare the effects of felzartamab to a placebo on symptoms and daily living activities in adult participants with gMG. A placebo looks like the study drug but does not contain any medicine.

The main question researchers want to answer is:

  • Does felzartamab increase the ability to perform daily activities after 26 weeks of treatment in participants with AChR antibodies?

Researchers will also learn more about:

  • How many participants have adverse events and serious adverse events during the study? Adverse events are health problems that may or may not be caused by the study drug.
  • How the body processes felzartamab
  • How felzartamab affects the participants' disease severity
  • How many participants' bodies make antibodies against felzartamab after treatment

This study will be done as follows:

  • Participants will join the study after signing an informed consent form, also known as an ICF.

  • Participants will be screened to check if they can join the study. Participants will then be assigned to a study group based on the type of antibodies they have.

    • If participants have AChR antibodies, they will be randomly assigned to receive either felzartamab or a placebo. Neither the participants nor the researchers will know if participants are getting the study drug or the placebo.
    • If participants have MuSK antibodies, they will receive felzartamab. In this group, the participants, study doctor, and study staff know which drug the participant is taking.
  • Both felzartamab and the placebo will be given as an intravenous (IV) infusion, which involves giving the drug into a vein.

  • During the study, participants will have regular clinic visits and phone calls. At the visits, participants will have blood and urine samples taken and will also have their overall health checked. The participants will also be asked questions about how they are feeling and how their gMG is affecting their daily lives.

  • After their last dose, participants will enter a follow-up safety period for more testing and monitoring of their health.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

The primary objective of this study is to evaluate the efficacy of felzartamab in participants with gMG compared with placebo. The secondary objectives of this study are to evaluate the efficacy, safety, pharmacokinetics (PK) of felzartamab and anti-drug antibodies (ADAs) in participants with gMG.

Study Type

Interventional

Enrollment (Estimated)

75

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Key Inclusion Criteria:

  • Documented diagnosis of gMG.
  • Myasthenia Gravis Foundation of America (MGFA) clinical Classification II to IVa at Screening and Randomization.
  • Corticosteroids must be administered orally on a daily or alternate-day schedule; pulse corticosteroid therapy is not permitted. Concomitant treatment with permitted acetylcholinesterase inhibitor (AChEIs) and/or allowed conventional immunosuppressant standard therapy (ISTs) is allowed, provided all therapies meet protocol-defined requirements.
  • Participants receiving AChEIs must have been on a stable dose prior to Randomization.
  • Participants receiving Azathioprine must be on treatment and a stable dose prior to Randomization.
  • Participants receiving other conventional immunosuppressive drugs (e.g., mycophenolate mofetil, mycophenolic acid, methotrexate, cyclosporine, tacrolimus), or other Sponsor-approved therapy) must be on treatment and on a stable dose prior to Randomization.
  • Participants should be up to date on all vaccinations in accordance with local country or regional public health authority guidelines, where feasible. Required vaccinations should be completed at least 4 weeks prior to screening, where applicable. A screening period extension may be permitted to allow completion of required vaccinations.

Key Exclusion Criteria:

  • MGFA Class I or IVb, or V at Screening.
  • History of myasthenic crisis requiring hospitalization, mechanical ventilation, or intensive care unit admission prior to Screening.
  • Anticipated need for rescue therapy between Screening and Randomization.
  • Congenital myasthenic syndrome, Lambert-Eaton myasthenic syndrome, or any other neuromuscular disorder that could confound the evaluation of gMG.
  • Thymectomy for benign thymoma within 12 months prior to Randomization or planned thymectomy during the study.
  • Unresected, active or recurrent thymoma.
  • History of malignancy within 5 years prior to Screening except for adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer, or other malignancies considered cured with minimal risk of recurrence, as determined by the Investigator.

NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cohort 1: Felzartamab or Placebo

Participants will receive multiple intravenous (IV) doses of felzartamab or placebo.

Administered IV

Administered IV

Other Names:
  • MOR202
  • MOR03087
  • TJ202
  • BIIB148
Experimental: Cohort 2: Felzartamab

Participants will receive multiple IV doses of felzartamab.

Administered IV

Other Names:
  • MOR202
  • MOR03087
  • TJ202
  • BIIB148

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Cohort 1: Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Week 26
Time Frame: Baseline, Week 26
Baseline, Week 26

Secondary Outcome Measures

Outcome Measure
Time Frame
Cohort 1: Change From Baseline in Quantitative Myasthenia Gravis (QMG) Total Score at Week 26
Time Frame: Baseline, Week 26
Baseline, Week 26
Cohorts 1 and 2: Number of Participants With Adverse Events (AEs) and Adverse Events of Special Interest (AESI)
Time Frame: From first dose of study drug up to end of study follow-up (Up to Week 52)
From first dose of study drug up to end of study follow-up (Up to Week 52)
Cohorts 1 and 2: Felzartamab Serum Concentrations Over Time
Time Frame: Predose and at multiple timepoints postdose up to Week 44
Predose and at multiple timepoints postdose up to Week 44
Cohorts 1and 2: Number of Participants with Anti-drug Antibodies (ADAs) Against Felzartamab
Time Frame: Baseline up to Week 52
Baseline up to Week 52

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Medical Director, Biogen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 19, 2026

Primary Completion (Estimated)

September 19, 2028

Study Completion (Estimated)

March 20, 2029

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 299MG201
  • 2026-527803-94 (Other Identifier: EU CT Number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.